



Intiva Licenses Intellectual Property Related to the Use of Cannabinoids to Treat Exposure to Nerve Agents

INTIVA Commences Drug Development of a Cannabinoid Formulation to Treat Exposure to Nerve Agents Including Sarin Gas

DENVER, CO, USA, May 16, 2017 /EINPresswire.com/ -- INTIVA Kotzker Pharmaceuticals Inc. ("INTIVA" or "the Company") has licensed certain intellectual property that includes patent applications relating to the application of cannabinoid receptor modulators, for investigating the use in acute treatment during exposure to organophosphorus nerve agents and/or organophosphorus insecticides.

INTIVA is completing a Pre-Investigational New Drug (IND) meeting request and anticipates meeting with the U.S. Food and Drug Administration (FDA) in the near future to discuss its proposed formulations and project development program.

"There is a great need for drugs that can treat the horrendous effects of nerve agents. We are hopeful that we will be able to develop and obtain FDA approval of this drug, and, if we are able to do so, that the product will be able to improve the chances of survivability and alleviate some of the disabling neurological after-effects of exposure to organophosphorus nerve agents, including sarin gas, and/or organophosphorus insecticides," stated Jeffrey Friedland, CEO of INTIVA.

INTIVA has assembled a team of experienced professionals in pharmaceutical development and regulatory compliance for this drug development project. INTIVA's team is developing formulations and clinical trial models to establish safety and efficacy, and is looking forward to its meeting with the FDA.

About INTIVA Kotzker Pharmaceuticals, Inc.

INTIVA Kotzker Pharmaceuticals, Inc. is a wholly-owned subsidiary of INTIVA BioPharma Inc., which is pursuing the formulation of cannabinoid-based drugs for the treatment of medical conditions and disorders.

INTIVA BioPharma Inc. is a subsidiary of INTIVA USA Inc., which is a wholly-owned subsidiary of INTIVA Inc., an Ontario, Canada corporation.

INTIVA Disclosure Notice:

This press release contains "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995. For this purpose, any statements contained herein or which are otherwise made by or on behalf of the Company that are not statements of historical facts may be deemed forward-looking statements. Without limiting the generality of the foregoing, words such as "may," "will," "to," "plan," "expect," "believe," "anticipate," "intend," "could," "should," "would," "estimate," or "continue," or the negative or other variations thereof or comparable terminology are intended to identify forward-looking statements. Readers are cautioned that all forward-looking statements involve

risk and uncertainties which may cause results to differ materially from those set forth in the statements. Such risks and uncertainties include, but are not limited to the following: the success of research and development activities and the speed with which regulatory authorizations and product launches may be achieved; government regulation generally; competitive developments; the ability to successfully market products domestically and internationally; difficulties or delays in manufacturing or issues relating to manufacturing capacity; commercial obstacles to the successful introduction of brand products generally; legal defense costs, insurance expenses, settlement costs, and the risk of an adverse decision or settlement relating to product liability, patent protection, governmental investigations, and other legal proceedings; the Company's ability to acquire and protect patents and other intellectual property both domestically and internationally; the absence of certainty regarding the receipt of required regulatory approval or the timing or terms of such approvals; any changes in business, political and economic conditions; business interruption due to hurricanes or other events outside of the Company's control.

Readers are cautioned not to place reliance on these forward-looking statements, which are valid only as of the date they were made. The Company undertakes no obligation to update or revise any forward-looking statements to reflect new information or the occurrence of unanticipated events or otherwise, except as expressly required by law.

Website www.INTIVABioPharma.com

Jeffrey Friedland
INTIVA Kotzker Pharmaceuticals, Inc.
1 800 497 2915
email us here

This press release can be viewed online at: <http://www.einpresswire.com>

Disclaimer: If you have any questions regarding information in this press release please contact the company listed in the press release. Please do not contact EIN Presswire. We will be unable to assist you with your inquiry. EIN Presswire disclaims any content contained in these releases.

© 1995-2017 IPD Group, Inc. All Right Reserved.